Treatment with levodopa and risk for malignant melanoma
ABSTRACT A large follow-up study in Denmark of 14,088 patients in whom Parkinson's disease was diagnosed at hospital showed a twofold higher incidence of malignant melanoma in these patients than in the general population. In a nested case-control study of 45 patients with malignant melanoma, 97 patients with nonmelanoma skin cancer, and 172 control subjects, we investigated the hypothesis that treatment with levodopa increases the risk for skin cancer. Information on diagnoses and treatment was retrieved from medical records. We observed a significant fourfold to fivefold increase in the risk for malignant melanoma in a subgroup of patients with a probable diagnosis of idiopathic Parkinson's disease as compared with other patients. There was apparently no effect of levodopa on the risk for malignant melanoma as indicated by an odds ratio of 1.0 (95% confidence interval, 0.8-1.3) per 1,000 g cumulative intake of the drug. We conclude that the increased rate of malignant melanoma observed in patients treated at hospital for Parkinson's disease is restricted to those with idiopathic Parkinson's disease, however, unrelated to the treatment with levodopa.
SourceAvailable from: Krzysztof Pawłowski[Show abstract] [Hide abstract]
ABSTRACT: Globally, malignant melanoma shows a steady increase in the incidence among cancer diseases. Malignant melanoma represents a cancer type where currently no biomarker or diagnostics is available to identify disease stage, progression of disease or personalized medicine treatment. The aim of this study was to assess the tissue expression of alpha-synuclein, a protein implicated in several disease processes, in metastatic tissues from malignant melanoma patients. A targeted Selected Reaction Monitoring (SRM) assay was developed and utilized together with stable isotope labeling for the relative quantification of two target peptides of alpha-synuclein. Analysis of alpha-synuclein protein was then performed in ten metastatic tissue samples from the Lund Melanoma Biobank. The calibration curve using peak area ratio (heavy/light) versus concentration ratios showed linear regression over three orders of magnitude, for both of the selected target peptide sequences. In support of the measurements of specific protein expression levels, we also observed significant correlation between the protein and mRNA levels of alpha-synuclein in these tissues. Investigating levels of tissue alpha-synuclein may add novel aspect to biomarker development in melanoma, help to understand disease mechanisms and ultimately contribute to discriminate melanoma patients with different prognosis.PLoS ONE 10/2014; 9(10). DOI:10.1371/journal.pone.0110804 · 3.53 Impact Factor
[Show abstract] [Hide abstract]
ABSTRACT: Epidemiological studies have reported the co-occurrence of Parkinson's disease and melanoma. Common genetic variants in the melanocortin 1 receptor (MC1R) gene which determines the skin and hair color are associated with melanoma. Here we investigated whether genetic variants in MC1R modulate the risk of Parkinson's disease by sequencing the entire gene in 870 Parkinson's disease patients and 736 controls ascertained from Spain. We found that the MC1R variant p.R160W (rs1805008) is marginally associated with Parkinson's disease (OR=2.10; gender- and age-adjusted P=0.009; Bonferroni-corrected P=0.063). Our results suggest that MC1R genetic variants modulate the risk of Parkinson's disease in the Spanish population. This article is protected by copyright. All rights reserved.Annals of Neurology 01/2015; 77(5). DOI:10.1002/ana.24373 · 11.91 Impact Factor
Actas Dermo-Sifiliográficas 05/2009; 100(4):331–332. DOI:10.1016/S0001-7310(09)70831-2